Engineering luminescent biosensors for point-of-care SARS-CoV-2 antibody detection

Autor: Leonel Torres, James Byrnes, Anum A. Glasgow, Michael J. Peluso, Taia T. Wang, Timothy J. Henrich, Kevin Leung, Alexander J. Martinko, Nikita S. Iyer, Xin X. Zhou, James A. Wells, Katarina Pance, Keirstinne Turcios, Cristina M. Tato, Bryan Greenhouse, Jeff E. Glasgow, Susanna K. Elledge, Shion A. Lim, Irene Lui
Jazyk: angličtina
Rok vydání: 2021
Předmět:
Saliva
Luminescence
Biosensing Techniques
Antibodies
Viral
Applied Microbiology and Biotechnology
Serology
0302 clinical medicine
Medicine
Viral
Lung
Whole blood
0303 health sciences
education.field_of_study
screening and diagnosis
biology
Chemistry
Vaccination
Detection
Infectious Diseases
Molecular Medicine
Antibody
Infection
Biotechnology
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Point-of-Care Systems
Population
Biomedical Engineering
Bioengineering
Antibodies
Article
COVID-19 Serological Testing
Vaccine Related
03 medical and health sciences
Biodefense
Humans
Luciferase
education
030304 developmental biology
Point of care
business.industry
SARS-CoV-2
Prevention
COVID-19
Virology
4.1 Discovery and preclinical testing of markers and technologies
Emerging Infectious Diseases
Good Health and Well Being
biology.protein
Immunization
business
Biosensor
030217 neurology & neurosurgery
Zdroj: Nat Biotechnol
medRxiv
article-version (status) pre
article-version (number) 1
Nature biotechnology, vol 39, iss 8
Popis: Current serology tests for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies mainly take the form of enzyme-linked immunosorbent assays, chemiluminescent microparticle immunoassays or lateral flow assays, which are either laborious, expensive or lacking sufficient sensitivity and scalability. Here we present the development and validation of a rapid, low-cost, solution-based assay to detect antibodies in serum, plasma, whole blood and to a lesser extent saliva, using rationally designed split luciferase antibody biosensors. This new assay, which generates quantitative results in 30 min, substantially reduces the complexity and improves the scalability of coronavirus disease 2019 (COVID-19) antibody tests. This assay is well-suited for point-of-care, broad population testing, and applications in low-resource settings, for monitoring host humoral responses to vaccination or viral infection.
Databáze: OpenAIRE
Externí odkaz: